FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to a method for treating or preventing cancer characterized by cancer cells expressing CLDN6, which comprises administering an antibody having the ability to bind to CLDN6 and chemotherapy to an oncological patient.
EFFECT: effective treatment or prevention of cancer characterized by cancer cells expressing CLDN6 due to the synergistic effect of a combination of chemotherapy and antibody.
17 cl, 23 dwg, 1 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES USEFUL IN DIAGNOSING CANCER | 2018 |
|
RU2815883C1 |
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| ANTIBODIES FOR TREATING CANCER, IN WHICH CLAUDIN 6 IS EXPRESSED | 2012 |
|
RU2816850C2 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| PREDICTION OF IMMUNOGENICITY OF T-CELL EPITOPES | 2014 |
|
RU2724370C2 |
| AMHRII BINDING COMPOUNDS FOR PREVENTING OR TREATING CANCER | 2018 |
|
RU2816523C2 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| AMHRII BINDING COMPOUNDS FOR THE PREVENTION OR TREATMENT OF LUNG CANCERS | 2018 |
|
RU2797506C2 |
